Upgrade to SI Premium - Free Trial

Ocugen (OCGN)

1.01 -0.01 (0.98%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Ocugen, Inc. (OCGN) PT Raised to $10 at H.C. Wainwright September 28, 2026 6:55 AM - StreetInsider Ocugen gets provisional approval in Bahamas for RP gene therapy OCU400 September 25, 2026 7:02 AM - StreetInsider Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa September 25, 2026 7:02 AM - StreetInsider Form 8-K Ocugen, Inc. For: Sep 21 September 23, 2026 6:01 AM - SEC Filing Form 4 Ocugen, Inc. For: Sep 09 Filed by: Musunuri Shankar September 11, 2026 9:14 PM - SEC Filing Ocugen, Inc. (OCGN) PT Lowered to $9.50 at H.C. Wainwright September 10, 2026 6:52 AM - StreetInsider Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD September 1, 2026 7:02 AM - StreetInsider Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration September 1, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming September Investor and Industry Conferences August 25, 2026 7:02 AM - StreetInsider Form DEFA14A Ocugen, Inc. August 14, 2026 6:10 AM - SEC Filing Form SCHEDULE 13G/A Ocugen, Inc. Filed by: Janus Henderson Group Ltd. August 13, 2026 12:42 PM - SEC Filing Form SCHEDULE 13G Ocugen, Inc. Filed by: STATE STREET CORP August 7, 2026 10:29 AM - SEC Filing Form 10-Q Ocugen, Inc. For: Jun 30 August 6, 2026 12:16 PM - SEC Filing Form 8-K Ocugen, Inc. For: Aug 06 August 6, 2026 8:31 AM - SEC Filing Ocugen (OCGN) Misses Q2 EPS by 2c August 6, 2026 7:53 AM - StreetInsider Ocugen Provides Business Update with Second Quarter 2026 Financial Results August 6, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming August Investor Conferences July 31, 2026 7:02 AM - StreetInsider Form DEFA14A Ocugen, Inc. July 30, 2026 4:37 PM - SEC Filing Form DEF 14A Ocugen, Inc. For: Sep 21 July 30, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G Ocugen, Inc. Filed by: BlackRock, Inc. July 29, 2026 3:21 PM - SEC Filing FDA grants RMAT designation to Ocugen's OCU410 for dry AMD July 29, 2026 7:03 AM - StreetInsider Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Relat July 29, 2026 7:01 AM - StreetInsider Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results July 28, 2026 4:01 PM - StreetInsider Form PRE 14A Ocugen, Inc. For: Sep 21 July 20, 2026 5:01 PM - SEC Filing Form 8-K Ocugen, Inc. For: Jul 13 July 13, 2026 8:31 AM - SEC Filing Ocugen signs MENA licensing deal for OCU400 gene therapy July 13, 2026 7:03 AM - StreetInsider Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa July 13, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming July Industry Conferences July 1, 2026 7:00 AM - StreetInsider Full Article List